Avid Bioservices, Inc.
2642 Michelle Drive, Suite 200
About Avid Bioservices, Inc.
Avid Bioservices Inc., located in Tustin CA, is a dedicated contract development and manufacturing organization (“CDMO”) focused on development and CGMP manufacturing of biopharmaceuticals products derived from mammalian cell culture. Avid provides a comprehensive range of process development, high quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 28 years of experience producing monoclonal antibodies, enzymes, and recombinant proteins in batch, fed-batch, and perfusion modes, Avid's services include CGMP clinical and commercial product manufacturing, purification, release and stability testing as well as regulatory strategy, submission and support. Avid also provides a variety of process development activities, including cell culture and feed optimization, analytical methods development, and product characterization.
Stock Symbol: CDMO
Take a virtual 3D tour of our Myford North facility featuring our CGMP single-use drug substance manufacturing suite and quality control labs.
97 articles with Avid Bioservices, Inc.
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2020 After Market Close on March 10, 2020
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the third quarter of fiscal year 2020 on March 10, 2020 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).
Avid Bioservices Appoints Timothy Compton as Chief Commercial OfficerCompany Adds Seasoned Professional with Over 20 Years of Commercial Operations and Sales Team Management Experience
Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, announced the appointment of Timothy Compton as chief commercial officer.
Achieved Strong Second Quarter Revenue of $18.3 Million and Gross Margin of 18%
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock - Dec. 04, 2019
Avid Bioservices, Inc. announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock.
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2020 After Market Close on December 9, 2019
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2020 on December 9, 2019
Avid Bioservices Announces Completion Of Expansion Of Process Development Capabilities And Laboratory Infrastructure
Company to Host Open House to Celebrate Official Launch of Newly Expanded Laboratories
Company Signs Top Ten Global Pharmaceutical Company as New Client and Expands Relationship with Existing Biotechnology Company Customer
It’s been a busy week for biopharma companies to name a chief executive officer. Over the past week, multiple companies have selected individuals to hold the top spots and guide the growth strategies of their companies.
Avid Bioservices, Inc. announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").
Avid Bioservices (NASD: CDMO) Selected to Provide Process Development and Clinical Manufacture for Novel Alzheimer's Drug
Avid Bioservices was selected by Acumen Pharmaceuticals to lead process development and clinical manufacturing of novel alzheimer's disease candidate.
Avid Bioservices Selected as Commercial Manufacturer for Critical Enzyme Replacement Therapy by Enzyvant, a Subsidiary of Roivant Sciences
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a company working to improve patient lives by providing high quality biologics manufacturing services to...
Avid Bioservices intends to use the cash for the expansion of its contract manufacturing business and general corporate purposes.
Avid Bioservices and Oncologie Enter Into Asset Assignment and Purchase Agreement for Avid’s PS-Targeting Program Including Bavituximab
In addition to bavituximab, the deal includes Avid’s other PS-targeting antibodies.
Dr. Lias succeeds Steven W. King, who resigned as president and chief executive officer of Peregrine to pursue other professional interests.
Ms. Kinjerski is a senior business development executive with more than 17 years of experience in the biopharmaceutical industry,
Avid Bioservices, Inc. Expands Manufacturing Capabilities With Installation And Validation Of Two MilliporeSigma Mobius 2,000-Liter Single-Use Bioreactors In Its Myford Facility
Avid Bioservices, Inc. Receives Mutliple 2017 CMO Leadership Awards For Quality, Reliability, Capabilties, Expertise And Compatibility
Avid Bioservices, Inc. To Participate In Avid Bioservices, Inc.'s 8th Annual The Bioprocessing Summit